Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Wave Life Sciences is a biotech company that designs RNA medicines to treat rare and common genetic disorders.
Wave Life Sciences is a biotech company that makes a special kind of medicine that works on RNA — the molecular messenger that carries instructions from your DNA to the parts of a cell that build proteins. When those instructions go wrong, you get disease. Wave's idea is to step in and fix or silence the bad message before it causes harm. Its platform, called PRISM, is the toolkit it uses to design these RNA medicines, and the company develops therapies for both rare disorders and more common ones.
The main thing Wave is known for is a type of drug called an antisense oligonucleotide. These are tiny, lab-made strands of genetic material that latch onto a specific RNA message inside cells. Depending on what the company designs, that can tell a cell to skip over a broken piece of a gene, to stop making a harmful protein, or to make more of a helpful one. The appeal is that you can target the root cause of a disease rather than just treating symptoms, and the "skip" approach is particularly useful for certain genetic conditions where a small error in a gene wrecks the whole protein. Wave's lead area is rare genetic diseases, especially ones caused by specific, well-understood mutations where a targeted RNA drug can make a real difference. Its most familiar programs include work in Duchenne muscular dystrophy and a genetic liver condition, and the company has pushed several candidates into clinical testing. The pitch to investors is a platform story: build one flexible set of chemical tools, then crank out multiple drug candidates that share the same underlying science. That can be more efficient than starting from scratch for every disease.
The hard part, and the honest part, is that this is a risky, cash-hungry business. RNA medicines are complex to manufacture and deliver to the right cells, clinical trials can fail late, and the field is crowded with competitors such as Ionis Pharmaceuticals, Sarepta Therapeutics, and Alnylam Pharmaceuticals. Wave has no approved product of its own and relies on partners and stock sales to fund its pipeline, so its value rises and falls on trial results and deal announcements. When a readout goes well, the stock can jump; when one disappoints, it can crater. That is the nature of a clinical-stage biotech: you are essentially betting on whether a clever scientific platform can turn into actual approved medicines.
Saved answer · last researched 15 Nov 2026